Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for Infectious Diseases, Including COVID-19

SAN DIEGO–(BUSINESS WIRE)– #COVID19–Selva has raised a $3 million Series A to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19.